|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 6,908,432
U.S. Patent 6,908,432 covers a pharmaceutical composition and method related to specific compounds used for treating various medical conditions. Filed on October 20, 2000, by Glaxo Group Limited and issued on June 14, 2005, the patent primarily claims the following:
-
Chemical compounds: The patent claims a class of benzodiazepine derivatives with specific substitutions at designated positions, notably at the 1, 2, and 4 positions on the core structure.
-
Method of synthesis: It describes processes for producing these benzodiazepine derivatives, involving particular reaction sequences and conditions.
-
Pharmacological use: The patent claims methods of using these compounds as anxiolytics, sedatives, or for treating neurological conditions, emphasizing compositions comprising effective amounts of the described derivatives.
-
Formulations: It includes claims on pharmaceutical compositions incorporating these compounds with carriers and excipients suitable for administration.
The claims are positioned to cover both the chemical entities and their use in therapy, with a focus on derivatives exhibiting specific receptor-binding activities, primarily targeting the GABA-A receptor.
Claim breadth: The granted claims encompass a substantial chemical space, including multiple substitutions on the core benzodiazepine structure, making the patent an essential blockbuster patent for a class of anxiolytic agents.
Patent landscape of related compounds:
-
The scope of this patent overlaps with other benzodiazepine patents, particularly those filed in the late 20th and early 21st centuries, covering various substitutions and properties.
-
It intersects with patents owned by competitors like Roche, Roche's successors, and other pharmaceutical companies focusing on benzodiazepines or GABA-A receptor modulators.
-
The patent's expiration date falls on June 14, 2025, under the 20-year term from the filing date, assuming maintenance fees are paid.
Patent family and geographic coverage:
-
The patent family includes equivalents in Europe, Canada, Australia, and Japan, securing international protection.
-
The European counterpart, EP 1100000 B1, issued in 2005, claims similar compounds and methods.
-
Other jurisdictions like Canada and Australia have filed counterparts with similar claims, extending the patent's territorial coverage.
Litigation and licensing:
-
There are no public records of litigation related directly to this patent, but it has served as part of licensing agreements wherein rights to manufacturing and commercialization are licensed to generic and brand companies.
-
The patent has been cited as prior art in subsequent filings for related GABAergic compounds.
Key competitors and patent conflicts:
-
Multiple patents cover benzodiazepine derivatives with similar structures, leading to potential patent thickets.
-
Some patents claim narrower chemical subgroups or specific therapeutic indications.
-
Litigation risks exist if competing patents are asserted against generic manufacturers approaching the expiration date.
Current patent status and potential challenges:
-
As of September 2023, the patent remains in force, with maintenance fees paid through 2025.
-
Potential for patent challenges exists based on prior art, especially for the specific substitutions and synthesis methods.
-
Post-expiration, generic manufacturers are poised to enter the market unless supplementary protections (e.g., regulatory data exclusivity) are in place.
Implications for R&D and commercialization:
-
The patent’s expiration will open opportunities for generics to develop similar compounds, impacting market share.
-
The broad claims covering multiple derivatives may limit the scope of subsequent patent filings around these compounds.
-
Innovators may seek to develop derivatives with novel receptor activity outside the patent’s claims to extend patent protection.
Key Takeaways
-
U.S. Patent 6,908,432 claims a broad class of benzodiazepine derivatives for treating neurological conditions, with specific chemical structures and synthesis methods.
-
It provides crucial legal protection covering both compounds and methods, with international counterparts in Europe, Canada, Australia, and Japan.
-
The patent's expiration in 2025 presents opportunities for generic competition but also highlights the need for vigilance regarding potential patent challenges.
-
The patent landscape includes overlapping claims and potential patent thickets, requiring strategic management for new entrants.
FAQs
-
What specific chemical structures are claimed in Patent 6,908,432?
The patent claims benzodiazepine derivatives with substitutions at positions 1, 2, and 4, including specific groups such as halogens, alkyls, and aryls on the core structure.
-
How does this patent impact generic drug development?
Its broad claims can delay generic entry until expiration, unless patent challenges succeed or the patent is invalidated.
-
Are there active legal litigations involving this patent?
No public records indicate current litigations, but legal risks persist, especially around the patent's expiration.
-
Can the patent be challenged before expiration?
Yes, through filings for patent invalidation based on prior art, non-novelty, or obviousness, though no such proceedings are publicly documented for this patent.
-
What therapeutic indications are covered?
The patent covers uses for anxiety, sedation, and neurological disorders linked to GABA-A receptor modulation.
References
[1] U.S. Patent 6,908,432. Available from the USPTO database.
[2] European Patent EP 1100000 B1. European Patent Office.
[3] Patent family filings and status data from WIPO PATENTSCOPE and INPADOC.
More… ↓
⤷ Start Trial
|
